Gapping up
In reaction to strong earnings/guidance: MCOX +19.7%, CBK +9.5%, TPLM +6.2%, ENZ +4.6%, LMNR +3.5%, BURL +3.3%, KANG +2.7%, HDS +1.8%, PBY +1.4%.
M&A news: CHS +15.6% (seeing reports that co is exploring going private), CLSN +12.1% (to acquire Egen; purchase price will be in exchange for cash and shares of Celsion totaling $14 mln - halted), ONNN +2% (to acquire Aptina Imaging for ~ $400 mln in cash; transaction is expected to be immediately accretive to earnings), MHR +1.6% (disclosed that it filed with the Australian Securities Exchange a notice of intention to make a takeover offer for Ambassador Oil and Gas).
Other news: RCPT +35.3% (reported positive Phase 2 results for RPC1063 in relapsing multiple sclerosis; Study met primary efficacy endpoint with statistical significance after 24 weeks of treatment), ACHN +32% (announces initiation of ACH-3422 dosing in HCV-infected patients and ability to resume sovaprevir clinical program for the treatment of chronic HCV), SPEX +11% (commences patent litigation against Huawei), AVNR +6.7% (announces positive outcome of Phase IIIb COMPASS Trial), INO +5.8% (initiates immune therapy trial for head & neck cancer caused by HPV ), SGMS +4.7% (IGT peer, names Gavin Isaacs as new CEO), ISIS +4.6% (earns $15 mln from AstraZeneca (AZN) for initiation of Phase 1 study of ISIS-AR Rx), CVA +3.9% (co announces cost saving initiative and intention to increase quarterly cash dividend to $0.25 per share from $0.18 per share), ONVO +2.2% (still checking), SAVE +1.7% (disclosed May 2014 traffic increased 18.7% year over year), NAVB +1.7% (reports data demonstrating potential of manocept platform to diagnose rheumatoid arthritis and kaposi's sarcoma), WRES +1.3% (increases in borrowing base to $175 mln under Senior Credit Facility, from $165 mln prior), CVEO +1% (Jana Partners disclosed 11.5% active stake in 13D filing).
Analyst comments: ENTR +3.9% (upgraded to Buy at Needham), S +2.3% (upgraded to Outperform from Neutral at Macquarie), JMEI +1.4% (initiated with a Buy at Goldman), IGT +1.3% (Wells Fargo sees potential sale of $15-17+/share), BUD +1.1% (tgt raised at RBC), RSG +1.1% (upgraded to Strong Buy from Mkt Perform at Raymond James ), AMCC +0.9% (initiated with a Buy at Canaccord Genuity), NFLX +0.7% (upgraded to Overweight from Equal Weight at Evercore), SWHC +0.5% (target raised to $21 from $18 at Northland Capital
)
In reaction to strong earnings/guidance: MCOX +19.7%, CBK +9.5%, TPLM +6.2%, ENZ +4.6%, LMNR +3.5%, BURL +3.3%, KANG +2.7%, HDS +1.8%, PBY +1.4%.
M&A news: CHS +15.6% (seeing reports that co is exploring going private), CLSN +12.1% (to acquire Egen; purchase price will be in exchange for cash and shares of Celsion totaling $14 mln - halted), ONNN +2% (to acquire Aptina Imaging for ~ $400 mln in cash; transaction is expected to be immediately accretive to earnings), MHR +1.6% (disclosed that it filed with the Australian Securities Exchange a notice of intention to make a takeover offer for Ambassador Oil and Gas).
Other news: RCPT +35.3% (reported positive Phase 2 results for RPC1063 in relapsing multiple sclerosis; Study met primary efficacy endpoint with statistical significance after 24 weeks of treatment), ACHN +32% (announces initiation of ACH-3422 dosing in HCV-infected patients and ability to resume sovaprevir clinical program for the treatment of chronic HCV), SPEX +11% (commences patent litigation against Huawei), AVNR +6.7% (announces positive outcome of Phase IIIb COMPASS Trial), INO +5.8% (initiates immune therapy trial for head & neck cancer caused by HPV ), SGMS +4.7% (IGT peer, names Gavin Isaacs as new CEO), ISIS +4.6% (earns $15 mln from AstraZeneca (AZN) for initiation of Phase 1 study of ISIS-AR Rx), CVA +3.9% (co announces cost saving initiative and intention to increase quarterly cash dividend to $0.25 per share from $0.18 per share), ONVO +2.2% (still checking), SAVE +1.7% (disclosed May 2014 traffic increased 18.7% year over year), NAVB +1.7% (reports data demonstrating potential of manocept platform to diagnose rheumatoid arthritis and kaposi's sarcoma), WRES +1.3% (increases in borrowing base to $175 mln under Senior Credit Facility, from $165 mln prior), CVEO +1% (Jana Partners disclosed 11.5% active stake in 13D filing).
Analyst comments: ENTR +3.9% (upgraded to Buy at Needham), S +2.3% (upgraded to Outperform from Neutral at Macquarie), JMEI +1.4% (initiated with a Buy at Goldman), IGT +1.3% (Wells Fargo sees potential sale of $15-17+/share), BUD +1.1% (tgt raised at RBC), RSG +1.1% (upgraded to Strong Buy from Mkt Perform at Raymond James ), AMCC +0.9% (initiated with a Buy at Canaccord Genuity), NFLX +0.7% (upgraded to Overweight from Equal Weight at Evercore), SWHC +0.5% (target raised to $21 from $18 at Northland Capital
)